Northwest & Ethical Investments L.P. Acquires Shares of 9,007 Cencora, Inc. $COR

Northwest & Ethical Investments L.P. bought a new position in Cencora, Inc. (NYSE:COR) during the 2nd quarter, Holdings Channel.com reports. The fund bought 9,007 shares of the company’s stock, valued at approximately $2,701,000.

Other institutional investors also recently bought and sold shares of the company. Artisan Partners Limited Partnership purchased a new stake in Cencora in the 2nd quarter worth $411,888,000. Invesco Ltd. increased its holdings in shares of Cencora by 42.1% in the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after buying an additional 1,125,661 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Cencora by 4,459.6% during the first quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock valued at $277,321,000 after buying an additional 975,362 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in Cencora by 8.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after buying an additional 787,858 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on COR. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a research report on Tuesday. Robert W. Baird upped their price target on shares of Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. TD Cowen lifted their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Wells Fargo & Company boosted their target price on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Finally, JPMorgan Chase & Co. upped their target price on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and a consensus target price of $371.09.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the sale, the chief executive officer directly owned 65,746 shares of the company’s stock, valued at $24,105,113.44. The trade was a 7.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 46,640 shares of company stock valued at $14,099,338 in the last quarter. 10.80% of the stock is currently owned by company insiders.

Cencora Price Performance

COR opened at $368.64 on Thursday. The business has a fifty day moving average of $332.58 and a 200 day moving average of $306.37. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $377.54. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The stock has a market cap of $71.47 billion, a P/E ratio of 37.93, a PEG ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same quarter last year, the firm posted $3.34 earnings per share. The business’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.